MCK News Alert Mckesson Corp (MCK) 224.89 02/14/2015 19:22:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mckesson Corp (MCK) 224.89 $MCK

The 10 Most Overpaid CEOs Running Multi-Billion Dollar Companies
at The Street - Fri Feb 13, 8:22AM CST
Which CEOs have the most egregious pay packages?
VIA: 69.08 (+1.02), MCK: 224.89 (+0.12), NBR: 12.73 (+0.52), FCX: 20.29 (+0.82), DISCA: 31.45 (+1.11), DIS: 104.17 (+0.59), CVS: 102.63 (-0.37), REGN: 402.40 (+0.66), ORCL: 43.93 (+0.04), CBS: 59.83 (+2.06)

Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:54AM CST
Charles River Laboratories (CRL) reported fourth-quarter 2014 earnings (excluding special items) of 81 cents per share, easily beating both the Zacks Consensus Estimate of 71 cents.
BIIB: 391.66 (-0.45), ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CRL: 73.61 (-0.33)

McKesson Honored as a 'Best Place to Work' for Second Year in a Row by Human Rights Campaign Foundation
Business Wire - Wed Feb 11, 7:30AM CST
McKesson Corporation was recognized again as one of the "Best Places to Work for LGBT Equality" by the Human Rights Campaign (HRC) Foundation. For the second year in a row McKesson scored 100% on the HRC's 2015 Corporate Equality Index, the national benchmarking tool on corporate policies and practices pertinent to lesbian, gay, bisexual and transgender (LGBT) employees.
MCK: 224.89 (+0.12)

McKesson Corporation to Present at the Cowen and Company 35th Annual Health Care Conference
Business Wire - Tue Feb 10, 3:10PM CST
McKesson Corporation (NYSE:MCK) today announced that James Beer, the company's executive vice president and chief financial officer, will present at the Cowen and Company 35th Annual Health Care Conference in Boston at 8:40 a.m. ET on Tuesday, March 3, 2015. Audio webcasts will be available live and archived on the company's Investor Relations website at http://investor.mckesson.com. A complete listing of upcoming events for the investment community is available on the company's Investor Relations website.
MCK: 224.89 (+0.12)

Health Care Providers and Services Equities Technical Momentum -- Cardinal Health, AmerisourceBergen, Community Health Systems, Select Medical Holdings, and McKesson
PR Newswire - Tue Feb 10, 7:35AM CST
Editor Note: For more information about this release, please scroll to bottom.
ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CAH: 86.08 (+0.04), CYH: 48.14 (+0.92), SEM: 14.32 (+0.11)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 4:37PM CST

FLIR: 33.01 (-0.23), ETR: 79.12 (-1.53), BCRX: 10.06 (-0.09), MCK: 224.89 (+0.12), HCN: 77.12 (-0.33), QUIK: 2.17 (+0.01), WAC: 20.29 (+2.57), RUSS: 11.59 (-0.81), ENTA: 33.30 (-0.44), LPI: 13.25 (+0.81)

Mckesson (MCK) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Fri Feb 06, 2:57PM CST
The following Mckesson (MCK) conference call took place on February 5, 2015, 05:00 PM ET. This is a transcript of that earnings call:
MCK: 224.89 (+0.12)

McKesson Corporation Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Fri Feb 06, 1:29PM CST

BDX: 143.71 (+0.72), MCK: 224.89 (+0.12), LO: 67.30 (-0.80), AMGN: 153.48 (+0.30), AWH: 40.50 (-0.19), PEP: 99.13 (-1.14), MKL: 731.94 (+4.29), ESRX: 84.90 (+0.40), GS: 189.00 (-0.78), R: 93.92 (+0.41), DTV: 87.51 (-0.32), BRK.B: 148.34 (-1.45), CIT: 46.17 (-0.36), BRK.A: 222,555.00 (-1,905.00)

Stocks Lose Steam On Greece Downgrade; McKesson Gains
at Investor's Business Daily - Fri Feb 06, 12:24PM CST
Stocks trimmed gains Friday afternoon after S&P cut Greece's credit rating to B- from B. The S&P 500 was up 0.3%, while the Nasdaq and the Dow Jones industrial average were each up less than 0.2%. All three were up from 0.4% to 0.5% at Friday's high....
GPRO: 45.27 (-0.02), MCK: 224.89 (+0.12), GRUB: 39.93 (+1.71), YELP: 47.53 (-0.10)

Rising Drug Demand Boosts McKesson Corporation
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 06, 8:52AM CST
McKesson Corporation delivers roughly one out of every three prescription drugs taken in the United States and it is also one of the nation's top health care IT firms. That suggests that McKesson -- and its $188 billion in annualized revenue -- is...
MCK: 224.89 (+0.12), MDRX: 11.80 (+0.04), CERN: 70.98 (+1.15)

Watch For Today's Momo Momentum Stock: McKesson (MCK)
at The Street - Fri Feb 06, 8:47AM CST
Trade-Ideas LLC identified McKesson (MCK) as a momo momentum candidate
MCK: 224.89 (+0.12)

McKesson Beats on Earnings & Revenues in Q3, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:32AM CST
McKesson Corporation (MCK) reported third-quarter fiscal 2015 (ended Dec 31, 2014) earnings of $2.89 per share, which comfortably beat the Zacks Consensus Estimate of $2.62.
ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CAH: 86.08 (+0.04), BIOD: 1.38 (-0.14)

McKesson posts higher GAAP earnings per diluted share of USD2.01 for Q3 fiscal 2015
M2 - Fri Feb 06, 4:11AM CST
Pharmaceutical company McKesson (NYSE:MCK) stated on Thursday that its GAAP earnings per diluted share from continuing operations were USD2.01 for third quarter ended 31 December 2014.
MCK: 224.89 (+0.12)

McKesson (MCK) Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 8:20PM CST

MCK: 224.89 (+0.12)

Look for Shares of McKesson to Potentially Pullback after Yesterday's 2.38% Rise
Comtex SmarTrend(R) - Thu Feb 05, 3:53PM CST
McKesson (NYSE:MCK) traded in a range yesterday that spanned from a low of $212.34 to a high of $217.29. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $216.11 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MCK: 224.89 (+0.12)

McKesson Set to Possibly Pullback After Yesterday's Rally of 2.38%
Comtex SmarTrend(R) - Thu Feb 05, 3:52PM CST
McKesson (NYSE:MCK) traded in a range yesterday that spanned from a low of $212.34 to a high of $217.29. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $216.11 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MCK: 224.89 (+0.12)

McKesson beats by $0.28, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 3:17PM CST

MCK: 224.89 (+0.12)

McKesson Reports Fiscal 2015 Third-Quarter Results
Business Wire - Thu Feb 05, 3:10PM CST
--Third-quarter GAAP earnings per diluted share from continuing operations of $2.01, up 187%.
MCK: 224.89 (+0.12)

Predictable Fast Growing Healthcare Dividend Growth And Growth Stocks For Your Retirement Portfolios: Part 5
Chuck Carnevale - at Seeking Alpha - Thu Feb 05, 10:51AM CST

JNJ: 99.62 (+1.18), ACT: 285.37 (+3.71), MCK: 224.89 (+0.12), THC: 44.30 (+0.75), UNH: 109.44 (-0.40), PFE: 34.64 (-0.23), CELG: 115.88 (+0.16)

Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead
at The Street - Wed Feb 04, 7:26PM CST
Many of the stocks hit hard Wednesday will rise again soon enough, Cramer says.
KMI: 41.97 (+0.21), MMM: 165.94 (+0.03), BX: 37.40 (+0.49), VMW: 84.68 (+1.06), OVAS: 44.32 (+0.87), NKE: 92.04 (+0.04), FRPT: 16.78 (-0.12), NBR: 12.73 (+0.52), WYNN: 159.34 (+4.62), RL: 135.20 (-0.60), UPS: 101.79 (+0.38), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), WHR: 213.23 (+0.18), JNJ: 99.62 (+1.18), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), SSYS: 67.16 (-0.34), PPC: 26.75 (+0.77), NPSP: 45.88 (+0.03), DG: 68.82 (+1.23), CAT: 85.13 (+1.60), MD: 71.32 (-0.06), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), WFM: 56.15 (-0.15), AMBA: 50.71 (-4.46), NSC: 109.91 (-0.17), MCK: 224.89 (+0.12), NUE: 48.90 (+0.55), HAL: 44.19 (+1.42), DIS: 104.17 (+0.59), COP: 69.88 (+1.84), BMY: 60.04 (+0.56), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), CELG: 115.88 (+0.16), HAIN: 59.48 (+0.45), TTWO: 28.40 (+0.96), GILD: 101.90 (+1.10), MCD: 95.65 (+0.56), FLT: 150.37 (+1.15), PG: 85.90 (-0.13)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Updated Category News Views 21

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 4

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
Partner Valuation Advisors Bolsters Team with Eichman

Updated Category News Views 7

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Continue Reading
Skiptown Expands in Georgia Amid Growing Demand

Updated Category News Views 24

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Continue Reading
Think Tank Pushes for Bold Parkinson's Prevention Plan

Updated Category News Views 25

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Continue Reading
Veterans Transitioning to Real Estate with Scholarships

Updated Category News Views 15

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Continue Reading
Special Needs Group Partners with MAST to Enhance Accessibility

Updated Category News Views 22

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Continue Reading
Omneky Outshines Competitors in AI Ad Scoring

Updated Category News Views 33

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 16

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
Honeywell Aerospace Faces Legal Turbulence in Fraud Case

Updated Category News Views 7

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Continue Reading

Top 5 Most Recently Viewed Articles

Pieridae Energy Limited Reports Strong Q3 2024 Performance

Updated Category News Views 58

Strong Financial and Operational Results from Pieridae Energy CALGARY, Alberta - Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) has announced its third quarter 2024 financial and operating results, showcasing an impressive production output and robust financial performance. The company achieved a production rate of 23,116 barrels of oil...

Continue Reading
Atea Pharmaceuticals Showcases Promising HCV Treatment Data

Updated Category News Views 136

Innovation in Hepatitis C Treatment by Atea Pharmaceuticals Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) has made a significant impact in the field of antiviral therapeutics through their ongoing research and development efforts. The company recently presented compelling data at The Liver Meeting 2024, highlighting the promising combination of bemnifosbuvir and ruzasvir for...

Continue Reading
Study Confirms Safety of Combined Eye Drops for Surgery Use

Updated Category News Views 172

Introduction to the Study A five-year pharmacovigilance study has confirmed the excellent safety profile of a fixed-dose combination eye drop developed by NTC. This eye drop combines an anti-inflammatory steroid and a quinolone antibiotic, designed for preventing and treating inflammation, as well as preventing infection after cataract surgery. Study Overview The findings...

Continue Reading
New Concerns Arise for Roblox Amid Allegations of Misreported Metrics

Updated Category News Views 203

Allegations Against Roblox: A Closer Look Roblox Corp (NYSE: RBLX) has recently come under fire after a report from Hindenburg Research highlighted potential discrepancies in its reported user metrics, leading to a notable decline in its stock prices. The gaming platform is being questioned for allegedly overstating its user metrics, including daily active users (DAUs)...

Continue Reading
uniQure N.V. Faces Investigation Amid Securities Fraud Concerns

Updated Category News Views 155

Understanding the uniQure N.V. Investigation Currently, uniQure N.V. is under investigation concerning possible violations of securities laws. This inquiry has raised significant concerns for shareholders and potential investors, driving many to seek assistance in understanding their rights moving forward. The investigation is being led by the DJS Law Group, an...

Continue Reading